Granulocyte elastase in acute myocardial infarction

Area of Science:

• Cardiology
• Biochemistry
• Immunology

Background:

• Neutrophil activation is implicated in acute myocardial infarction (AMI).
• Polymorphonuclear granulocytes elastase (PMN elastase) in complex with alpha-1 proteinase inhibitor serves as a marker for neutrophil activation.
• Assessing PMN elastase may offer insights into AMI pathophysiology and complications.

Purpose of the Study:

• To investigate plasma concentrations of PMN elastase in patients with AMI.
• To evaluate the relationship between PMN elastase levels and myocardial injury markers.
• To determine if thrombolytic therapy influences PMN elastase levels and if PMN elastase can predict AMI complications.

Main Methods:

• Serial peripheral venous blood samples were collected from 39 AMI patients.
• Measurements included PMN elastase, creatine kinase, and cardiac troponin T.
• Patients were categorized based on thrombolytic therapy (streptokinase, urokinase, recombinant tissue plasminogen activator) or conventional treatment, and presence of complications.

Main Results:

• All AMI patients exhibited elevated PMN elastase levels.
• Peak and cumulative PMN elastase concentrations did not strongly correlate with myocardial injury markers.
• PMN elastase levels increased within 6 hours of thrombolytic therapy initiation, unlike in conventionally treated patients.
• Significantly higher PMN elastase concentrations were observed in AMI patients with complications (cardiac arrest, rupture, shock) compared to uncomplicated cases.
• Changes in PMN elastase levels paralleled or preceded clinical presentation in complicated cases.

Conclusions:

• Thrombolytic treatment does not appear to significantly alter systemic neutrophil activation in AMI.
• Plasma PMN elastase is a potential biomarker for monitoring and identifying complications in acute myocardial infarction.
• Further research could explore the prognostic value of PMN elastase in AMI management.